MAIA Biotechnology director buys 15,000 shares at $1.04 average

MAIA Biotechnology director reports open-market stock purchase Stan V. Smith, a director of MAIA Biotechnology, Inc., reported buying 15,000 shares of MAIA common stock on 11/26/2025.

Rhea-AI Filing Summary

MAIA Biotechnology director reports open-market stock purchase

Stan V. Smith, a director of MAIA Biotechnology, Inc., reported buying 15,000 shares of MAIA common stock on 11/26/2025. The purchase was made in the open market at a weighted average price of $1.0388 per share, with individual trades executed between $1.03 and $1.051. Following this transaction, Mr. Smith beneficially owned 1,364,289 shares of MAIA common stock, held indirectly through The Stan V. Smith Trust Dated 1993.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Smith Stan

Role Director

Bought 15,000 shs ($16K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	15,000	$1.0388	$16K

Holdings After Transaction: Common Stock — 1,364,289 shares (Indirect, See Footnote)

Footnotes (2)

1. F1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.051, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
2. F2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAIA (MAIA) disclose in this Form 4?

The filing shows that director Stan V. Smith purchased 15,000 shares of MAIA Biotechnology, Inc. common stock in an open-market transaction on 11/26/2025.

At what price did the MAIA (MAIA) director buy the shares?

The shares were bought at a weighted average price of $1.0388 per share, with individual purchase prices ranging from $1.03 to $1.051, inclusive.

How many MAIA (MAIA) shares does the reporting person beneficially own after the transaction?

After the reported transaction, Stan V. Smith beneficially owned 1,364,289 shares of MAIA common stock.

How are the MAIA (MAIA) shares held by the reporting person structured?

The filing states that these securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993, indicating indirect ownership.

What is the relationship of the reporting person to MAIA (MAIA)?

The reporting person, Stan V. Smith, is identified as a Director of MAIA Biotechnology, Inc. on the Form 4.

Does the Form 4 provide detail on the price breakdown for the MAIA (MAIA) share purchases?

Yes. It notes that the reported price is a weighted average and that the shares were purchased in multiple transactions between $1.03 and $1.051. Mr. Smith undertakes to provide full trade‑by‑trade detail upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/01/2025 - 06:14 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Stan

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/26/2025		P		15,000	A	$1.0388(1)	1,364,289	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.051, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

2. These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

	/s/ Stan V. Smith	11/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.